A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
Memory Care Best Practices and Research, Memory Care Education
The Alzheimer’s Association of America is hosting National Memory Screening Day, November 18. During the event, healthcare professionals are providing...
End of Life, Health and Wellness, Health Care
The SCAN Foundation and Avalere Health have created a new comprehensive brochure “Establishing the Financial Sustainability of Your Organization’s Per...
All About Alzheimer’s: The Power of Chocolate, the Wonder of Walnuts and the Down Syndrome Connection
Facts and Figures, Memory Care Best Practices and Research, Memory Care Education, Reports
Chocolate lovers rejoice – a new study found that a natural compound found in cocoa could reverse age-related memory loss. The study in Nature Neurosc...
Active & Engaged Seniors, Independence, Managed Risk
The American Geriatrics Society and the National Highway Traffic Safety Administration have teamed up to educate healthcare providers and the public a...
Active & Engaged Seniors, cheatsheet, Family Relations, Memory Care Best Practices and Research, Memory Care Education
Alzheimer’s is a transformative, thieving disease, robbing its targets of precious memories and much more and affecting women twice as often as men. T...
cheatsheet, Engage, Health and Wellness, Managed Risk
News and information about the recent Ebola virus disease outbreak in the United States is constantly changing. Here’s a roundup of helpful websites a...
Stories and news about Ebola are omnipresent today and whenever there’s a health scare in the headlines, scammers are sure to follow close behind.
cheatsheet, Clinical Quality and Quality Care Delivery, Federal Agency Activity, Health and Wellness, Managed Risk
The Centers for Disease Control and Prevention has issued infection prevention and control recommendations for hospitalized patients with known or sus...
cheatsheet, End of Life, Facts and Figures, Health and Wellness, Reports
The National Center for Health Statistics has released its latest data for mortality in the United States in 2012, revealing that life expectancy has ...
Federal Agency Activity, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education
The National Institutes of Health announced a set of investments totaling $46 million to support the goals of the BRAIN initiative, a large-scale effo...